Dr. Jennifer Bath, CEO of MindWalk, will participate in a virtual panel on AI-driven drug discovery, alongside Absci and a leading AI compute provider, during Jones AI Day on June 15, 2026.
The panel, titled “Partnering to Power the New Era of Drug Discovery,” will delve into how advancements in high-performance computing and generative AI can overcome traditional obstacles in drug development. This includes addressing long screening timelines and tackling historically challenging targets. Moderated by analysts from Jones Research, the discussion aims to highlight the integration of biological data and AI technology in enhancing drug discovery processes.
MindWalk, known for its innovative HYFT® technology, emphasizes the importance of a robust biological context layer, which it believes is crucial for effective AI applications in life sciences. Dr. Bath is expected to articulate how this enriched context layer enhances the reliability of AI models in drug discovery, making them more trustworthy for regulated environments. She notes that the core challenge in drug discovery lies not in computational power but in the fragmented nature of biological data.
This event underscores the growing intersection of AI and life sciences, with companies like MindWalk leading the charge to make AI applications more effective and reliable. As the industry evolves, the focus on integrating biological knowledge with advanced computing could significantly reshape drug discovery methodologies, paving the way for breakthroughs in treating complex diseases.